SEC EDGARAUG 311 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.51 ($514.26–$524.42, $4.92M total) across 11 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · ROTHBLATT MARTINE A

Published Aug 31, 2026, 8:34 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 31, 2026, 9:34 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$UTHR

Bearish

medium confidence

Mentioned

$UTHR

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$UTHRBearishLow

Why it matters

The disclosed sale provides fresh data on insider sentiment, which can influence short‑term trading decisions.

Market read

Insider sales by top executives are closely watched; this filing adds a new data point for traders evaluating United Therapeutics.

What to watch

Potential upcoming corporate actions or financing needs that prompted the planned sale; also, the CEO's continued large ownership may mitigate negative perception.

Relevance 5/10Novelty 7/10Timing: post‑filing today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of material information.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$UTHRBearishMedium confidence

Context

CEO Martine Rothblatt sold $4.9M of United Therapeutics shares via a 10b5‑1 plan on Aug 28, reducing her stake to 324,443 shares.

Expected impact

Possible modest downside of 2‑4% over the next few days as the market digests the sale.

Evidence & confidence

The sale size is material for a mid‑cap biotech and the insider is the top executive; however, the transaction was pre‑arranged, limiting the informational edge.

Market effects

Sector

May raise concerns for the biotech/pharma sector about insider sentiment, but limited broader impact.

Regional

Primarily U.S. market; no notable regional effect.

Global

Low global relevance beyond United Therapeutics investors.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect a change in confidence; the stock could remain stable.

Key entities

Company
United Therapeutics Corp
Biopharmaceutical company focused on developing therapies for rare diseases.
Executive
Martine A. Rothblatt
Chairperson & CEO of United Therapeutics, insider reporter of the transaction.

Read at source ← All news

SEP 11

$UTHRHigh

United Therapeutics Moves to Complete Its $2 Billion Buyback, Betting the Market Is Underpricing Its Pipeline

United Therapeutics (UTHR) announced a $477.6M accelerated share repurchase agreement with Citibank, completing its $2B buyback program. CEO Martine Rothblatt stated the move reflects confidence in the company's undervalued pipeline. The company has returned $4B to shareholders in 2.5 years.

biobuzz.io2 min

SEP 11

$UTHRHigh

United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

United Therapeutics (UTHR) committed $477.6M to a share repurchase, part of its $2B authorization. The company has $3.8B in cash and investments, with pending FDA reviews for ralinepag and Nebulized Tyvaso. Q2 revenue declined 2% to $783.3M, with Tyvaso revenue down 4%. The buyback's impact on shareholder value depends on pipeline success and cash generation.

insidermonkey.com2 min

SEP 10

$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min

SEP 9

$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min

SEP 9

$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min

SEP 8

$UTHRHighAI 8/10

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi

United Therapeutics (UTHR) agreed to repurchase $477.6M of its common stock through an accelerated share repurchase with Citi. The company will pay upfront and receive an initial 719,376 shares, with final count based on average daily VWAP. Settlement is expected in Q4 2026.

tradingview.com1 min